1 May 2020 in Clinical Lung Cancer
20 May 2018 in Journal of Clinical Oncology
6504Background: Lung cancer is the leading cause of cancer related mortality in the United States. Since 2013, the United States Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose computed tomography (LDCT) for those aged 55-80 years for those who have smoked at least 30 pack years who currently smoke or have quit within the past 15 years. Current literature has provided only estimates of lung cancer screening since implementation. Our study aims to present the number of screening LDCTs being performed across the United States. Methods: Using data from the Lung Cancer Screening Registry (LCSR) provided by the American College of Radiology (ACR) in 2016, we collected the total number of LDCT from all 1,796 accredited radiographic screening sites. We used the 2015 National Health Interview Survey (NHIS) to estimate screening eligible smokers per USPSTF criteria and compared them with the 2016 LCSR reported screens. Analyses excluded respondents with missing da...
1 August 2018 in Seminars in Oncology
1 October 2018 in American Journal of Clinical Oncology
Background: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. Methods: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data. Hospital medical records were reviewed to obtain information on demographics, diagnosis, treatment, and date of last follow-up visit. Characteristics of patients with ≥5 years of follow-up care were compared with those who were LFU. Results: In total, 487 patients received chemotherapy and 304 died (62%) during the 5-year follow-up period. Among the 183 cancer patients who were known to be alive at 5 years, 92 (50%) were LFU and 50% (46/92) of this LFU group were LFU within 1 year of diagnosis. At 5 years, follow-up care was continuing for 55% of women, compared with 39% of men. The highest proportion of follow-up was observed among lung cancer patients (84%), followed by patients with breast cancers (63%) and gastrointestinal cancers (40%). Patients with hematological cancers had the lowest follow-up proportion at 5 years (29%) (P<0.05). Follow-up was not significantly associated with age (P=0.48), insurance status(P=0.29), and race(P=0.06). Conclusions: It is estimated that 65% of the cancer survivors in the United States are ≥5 years beyond their diagnosis but there is little data on oncology follow-up rates. In our retrospective study of 183 patients who were treated with chemotherapy only 49.7% continue to follow-up at their treatment center. LFU has important implications in planning long-term care strategies for cancer survivors and in survivorship research.
16 September 2019 in Medical Oncology
1 April 2020 in Current Problems in Cancer